Latest / tv.qiagenbioinformatics.com
Accelerating biomarker signature discovery for rare diseases using curated...
Identifying molecular signatures for rare diseases is challenging, mainly due to limited sample sizes and heterogenous data. Researchers must often piece together fragmented evidence to uncover shared biological mechanisms. Though inescapable, this process can be more efficient.
See how QIAGEN OmicSoft Lands and Ingenuity Pathway Analysis (IPA) streamlines biomarker signature discovery using curated real-world datasets and powerful causal analytics. With automation powered by SQL, Python and R APIs, OmicSoft and IPA enable scalable, reproducible analyses across multiple disease contexts…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.